Ranbaxy Pharmaceuticals Ltd is a pharmaceutical company located in New
Delhi. Two of its subsidiary plants in
Dewas and Paonta, which develop generic drugs, have been blocked by the US Food
and Drug Administration. 30 of the
generic drugs they produce will not be allowed to be sold in the United States.
Both plants failed to meet the Good
Manufacturing Practice, a standard developed and required for prescription
Although these drugs account for about
40% of Ranbaxy’s revenues, the company argues that it will have minimal impact
on their income. Some examples of
blocked drugs include:
will be available in the US, but will be forced to undergo heavy supervision
and warnings to consumers that these drugs did not pass all safety inspections
usually employed by the USDA.